Deborah H. Sutton

TL;DR: Four new reagents termed immune-mobilizing monoclonal TCRs against cancer (ImmTACs) effectively redirected T cells to kill cancer cells expressing extremely low surface epitope densities and suppressed tumor growth in vivo.

TL;DR: Phage display is used to isolate and enhance a T-cell antigen receptor originating from a CTL line derived from an infected person and specific for the immunodominant HLA-A*02-restricted, HIVgag-specific peptide SLYNTVATL (SL9), which effectively controlled wild-type and mutant strains of HIV at effector-to-target ratios that could be achieved by T- cell therapy.

TL;DR: In vivo ImmTAC-NYE efficacy was tested in a tumor model in which human lymphocytes were stably co-engrafted into NSG mice harboring tumor xenografts; efficacy was observed in both tumor prevention and established tumor models using a GFP fluorescence readout.

TL;DR: By single molecule fluorescence microscopy, HLA-peptide presentation is directly visualize for the first time, demonstrating that NY-ESO-1/LAGE-1-positive tumor cells present 10–50 NY- ESO- 1/Lage-1157–165 epitopes per cell.

TL;DR: It is indicated that peptide concentrations in the low nanomolar range are required for T2 cells to present TAAs in extents that are comparable to those of malignant cells.